We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Verrica Pharmaceuticals Inc (VRCA) USD0.0001

Sell:$6.14 Buy:$7.26 Change: $0.38 (5.07%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Change: $0.38 (5.07%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Change: $0.38 (5.07%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Contact details

10 N High St Ste 200
United States
+1 (484) 4533300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$318.15 million
Shares in issue:
42.42 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Ted White
    President, Chief Executive Officer, Director
  • P. Terence Kohler
    Chief Financial Officer
  • Christopher Hayes
    General Counsel, Company Secretary, Chief Legal Office
  • Joe Bonaccorso
    Chief Commercial Officer
  • Gary Goldenberg
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.